Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Fig. 3

Tumor infiltrating lymphocyte (TIL) clonality in primary melanoma tumor biopsies (Primary Tumor) and post-treatment metastatic melanoma biopsies (Post Tx Met; approximately 6–8 weeks from baseline). Higher TIL clonality in primary tumor, and more so following neoadjuvant immunotherapy, was associated with improved relapse free survival (RFS)

Back to article page